DrugRepV Browse Page


DrugRepV browse page allows user to take a glance of the particular antiviral agent.Fields in the webpage is hylerlinked ot various external repositories like DrugBank, PubChem, Clinicaltrials.gov,and PubMed.User can explore the biological, Clinical, Chemical, and Structural details of every repurposed drug candidate.By clicking on the table header arrows, user can sort entries in ascending or descending order.


Total number of Records for Picornaviridae are 57




DrugRepV_ID Antiviral Name
Drug type
Primary Indication
Secondary Indication
Strain
Pathways
Assay
Activity
Clinical Status
 References
DrugRepV_7058Fenretinide
Anticancer
Prostate cancer | Breast cancer | Macular degeneration
Polio virus
NA
Pathway
Plaque assay
Decrease
Investigational
25313218
DrugRepV_7089Teicoplanin
Antiinfectives For Systemic Use
Bacterial infections
Polio virus
Sabin
Pathway
Plaque assay
No significant effect
Approved
26585243
DrugRepV_7107Arbidol
NA
Viral infection
Polio virus
NA
Pathway
Plaque assay
Decrease (50 %)
Phase IV
22028179
DrugRepV_7514Quinacrine
NA
Malaria | Giardiasis | Cutaneous leishmaniasis | Management of malignant effusions
Polio virus
NA
Pathway
NA
Decrease (50 %)
Investigational
31307979
DrugRepV_7517Aloe-emodin
NA
NA
Enterovirus
EV71
Pathway
Plaque assay
Decrease (50 %)
NA
18701259
DrugRepV_7518Aloe-emodin
NA
NA
Enterovirus
EV71
Pathway
Plaque assay
Decrease (50 %)
NA
18701259
DrugRepV_7525Telaprevir
Antiinfectives For Systemic Use
Hepatitis C virus
Enterovirus
US/KY/14-18953
Pathway
Cytopathic effect (CPE) assay
Decrease (50 %)
Approved
30674624
DrugRepV_7526Telaprevir
Antiinfectives For Systemic Use
Hepatitis C virus
Enterovirus
US/MO/14-18949
Pathway
Cytopathic effect (CPE) assay
Decrease (50 %)
Approved
30674624
DrugRepV_7527Telaprevir
Antiinfectives For Systemic Use
Hepatitis C virus
Enterovirus
US/MO/14-18947
Pathway
Cytopathic effect (CPE) assay
Decrease (50 %)
Approved
30674624
DrugRepV_7528Telaprevir
Antiinfectives For Systemic Use
Hepatitis C virus
Enterovirus
US/IL/14-18952
Pathway
Cytopathic effect (CPE) assay
Decrease (50 %)
Approved
30674624
DrugRepV_7529Telaprevir
Antiinfectives For Systemic Use
Hepatitis C virus
Enterovirus
US/IL/14-18956
Pathway
Cytopathic effect (CPE) assay
Decrease (50 %)
Approved
30674624
DrugRepV_7530Telaprevir
Antiinfectives For Systemic Use
Hepatitis C virus
Enterovirus
US/KY/14-18953
Pathway
Cytopathic effect (CPE) assay
Decrease (50 %)
Approved
30674624
DrugRepV_7531Telaprevir
Antiinfectives For Systemic Use
Hepatitis C virus
Enterovirus
US/KY/14-18953
Pathway
Cytopathic effect (CPE) assay
Decrease (50 %)
Approved
30674624
DrugRepV_7532Telaprevir
Antiinfectives For Systemic Use
Hepatitis C virus
Enterovirus
US/KY/14-18953
Pathway
Cytopathic effect (CPE) assay
Decrease (50 %)
Approved
30674624
DrugRepV_7533Telaprevir
Antiinfectives For Systemic Use
Hepatitis C virus
Enterovirus
US/KY/14-18953
Pathway
Cytopathic effect (CPE) assay
Decrease (50 %)
Approved
30674624
DrugRepV_7986Silymarin
Alimentary tract and metabolism
NA
Enterovirus
41
Pathway
Plaque assay
Decrease (50 %)
NA
32293397
DrugRepV_7987Baicalein
Plant extract
Influenza
Enterovirus
41
Pathway
Plaque assay
Decrease (50 %)
Phase II
32293397
DrugRepV_80202-(6-{[1-carboxy-2-(2-phenyl-1H-indol-3-yl)ethyl]carbamoyl}-4-(2-{[1-carboxy-2-(2-phenyl-1H-indol-3-yl)ethyl]carbamoyl}ethyl)-4-nitrohexanamido)-3-(2-phenyl-1H-indol-3-yl)propanoic acid
NA
NA
Enterovirus
BrCr
Pathway
NA
Decrease (50 %)
NA
31809045
DrugRepV_80212-[6-({1-carboxy-2-[2-(2-fluorophenyl)-1H-indol-3-yl]ethyl}carbamoyl)-4-[2-({1-carboxy-2-[2-(2-fluorophenyl)-1H-indol-3-yl]ethyl}carbamoyl)ethyl]-4-nitrohexanamido]-3-[2-(2-fluorophenyl)-1H-indol-3-yl]propanoic acid
NA
NA
Enterovirus
BrCr
Pathway
NA
Decrease (50 %)
NA
31809045
DrugRepV_80222-[6-({1-carboxy-2-[2-(4-nitrophenyl)-1H-indol-3-yl]ethyl}carbamoyl)-4-[2-({1-carboxy-2-[2-(4-nitrophenyl)-1H-indol-3-yl]ethyl}carbamoyl)ethyl]-4-nitrohexanamido]-3-[2-(4-nitrophenyl)-1H-indol-3-yl]propanoic acid
NA
NA
Enterovirus
BrCr
Pathway
NA
Decrease (50 %)
NA
31809045
DrugRepV_80233-[2-(4-bromophenyl)-1H-indol-3-yl]-2-[6-({2-[2-(4-bromophenyl)-1H-indol-3-yl]-1-carboxyethyl}carbamoyl)-4-[2-({2-[2-(4-bromophenyl)-1H-indol-3-yl]-1-carboxyethyl}carbamoyl)ethyl]-4-nitrohexanamido]propanoic acid
NA
NA
Enterovirus
BrCr
Pathway
NA
Decrease (50 %)
NA
31809045
DrugRepV_80242-{6-[(1-carboxy-2-{2-[4-(trifluoromethyl)phenyl]-1H-indol-3-yl}ethyl)carbamoyl]-4-{2-[(1-carboxy-2-{2-[4-(trifluoromethyl)phenyl]-1H-indol-3-yl}ethyl)carbamoyl]ethyl}-4-nitrohexanamido}-3-{2-[4-(trifluoromethyl)phenyl]-1H-indol-3-yl}propanoic acid
NA
NA
Enterovirus
BrCr
Pathway
NA
Decrease (50 %)
NA
31809045
DrugRepV_80252-[6-({1-carboxy-2-[2-(4-methoxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)-4-[2-({1-carboxy-2-[2-(4-methoxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)ethyl]-4-nitrohexanamido]-3-[2-(4-methoxyphenyl)-1H-indol-3-yl]propanoic acid
NA
NA
Enterovirus
BrCr
Pathway
NA
Decrease (50 %)
NA
31809045
DrugRepV_80263-(3-{2-carboxy-2-[6-({1-carboxy-2-[2-(3-carboxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)-4-[2-({1-carboxy-2-[2-(3-carboxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)ethyl]-4-nitrohexanamido]ethyl}-1H-indol-2-yl)benzoic acid
NA
NA
Enterovirus
BrCr
Pathway
NA
Decrease (50 %)
NA
31809045
DrugRepV_80274-(3-{2-carboxy-2-[6-({1-carboxy-2-[2-(4-carboxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)-4-[2-({1-carboxy-2-[2-(4-carboxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)ethyl]-4-nitrohexanamido]ethyl}-1H-indol-2-yl)benzoic acid
NA
NA
Enterovirus
BrCr
Pathway
NA
Decrease (50 %)
NA
31809045
DrugRepV_80285-(3-{2-carboxy-2-[6-({1-carboxy-2-[2-(3,5-dicarboxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)-4-[2-({1-carboxy-2-[2-(3,5-dicarboxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)ethyl]-4-nitrohexanamido]ethyl}-1H-indol-2-yl)benzene-1,3-dicarboxylic acid
NA
NA
Enterovirus
BrCr
Pathway
NA
Decrease (50 %)
NA
31809045
DrugRepV_80293-{3-[2-carboxy-2-(3-{3-[2-({1-carboxy-2-[2-(3-carboxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)ethoxy]-2,2-bis({[2-({1-carboxy-2-[2-(3-carboxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)ethoxy]methyl})propoxy}propanamido)ethyl]-1H-indol-2-yl}benzoic acid
NA
NA
Enterovirus
BrCr
Pathway
NA
Decrease (50 %)
NA
31809045
DrugRepV_80304-{3-[2-carboxy-2-(3-{3-[2-({1-carboxy-2-[2-(4-carboxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)ethoxy]-2,2-bis({[2-({1-carboxy-2-[2-(4-carboxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)ethoxy]methyl})propoxy}propanamido)ethyl]-1H-indol-2-yl}benzoic acid
NA
NA
Enterovirus
BrCr
Pathway
NA
Decrease (50 %)
NA
31809045
DrugRepV_80315-{3-[2-carboxy-2-(3-{3-[2-({1-carboxy-2-[2-(3,5-dicarboxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)ethoxy]-2,2-bis({[2-({1-carboxy-2-[2-(3,5-dicarboxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)ethoxy]methyl})propoxy}propanamido)ethyl]-1H-indol-2-yl}benzene-1
NA
NA
Enterovirus
BrCr
Pathway
NA
Decrease (50 %)
NA
31809045
DrugRepV_80324-[(3-{2-carboxy-2-[3-(3-{2-[(1-carboxy-2-{1-[(4-carboxyphenyl)methyl]-1H-indol-3-yl}ethyl)carbamoyl]ethoxy}-2,2-bis({2-[(1-carboxy-2-{1-[(4-carboxyphenyl)methyl]-1H-indol-3-yl}ethyl)carbamoyl]ethoxy}methyl)propoxy)propanamido]ethyl}-1H-indol-1-yl)me
NA
NA
Enterovirus
BrCr
Pathway
NA
Decrease (50 %)
NA
31809045
DrugRepV_80332-[6-({1-carboxy-2-[2-(4-nitrophenyl)-1H-indol-3-yl]ethyl}carbamoyl)-4-[2-({1-carboxy-2-[2-(4-nitrophenyl)-1H-indol-3-yl]ethyl}carbamoyl)ethyl]-4-nitrohexanamido]-3-[2-(4-nitrophenyl)-1H-indol-3-yl]propanoic acid
NA
NA
Enterovirus
BrCr
Pathway
NA
Decrease (90 %)
NA
31809045
DrugRepV_80343-(3-{2-carboxy-2-[6-({1-carboxy-2-[2-(3-carboxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)-4-[2-({1-carboxy-2-[2-(3-carboxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)ethyl]-4-nitrohexanamido]ethyl}-1H-indol-2-yl)benzoic acid
NA
NA
Enterovirus
BrCr
Pathway
NA
Decrease (90 %)
NA
31809045
DrugRepV_80355-(3-{2-carboxy-2-[6-({1-carboxy-2-[2-(3,5-dicarboxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)-4-[2-({1-carboxy-2-[2-(3,5-dicarboxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)ethyl]-4-nitrohexanamido]ethyl}-1H-indol-2-yl)benzene-1,3-dicarboxylic acid
NA
NA
Enterovirus
BrCr
Pathway
NA
Decrease (90 %)
NA
31809045
DrugRepV_80363-{3-[2-carboxy-2-(3-{3-[2-({1-carboxy-2-[2-(3-carboxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)ethoxy]-2,2-bis({[2-({1-carboxy-2-[2-(3-carboxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)ethoxy]methyl})propoxy}propanamido)ethyl]-1H-indol-2-yl}benzoic acid
NA
NA
Enterovirus
BrCr
Pathway
NA
Decrease (90 %)
NA
31809045
DrugRepV_80374-{3-[2-carboxy-2-(3-{3-[2-({1-carboxy-2-[2-(4-carboxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)ethoxy]-2,2-bis({[2-({1-carboxy-2-[2-(4-carboxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)ethoxy]methyl})propoxy}propanamido)ethyl]-1H-indol-2-yl}benzoic acid
NA
NA
Enterovirus
BrCr
Pathway
NA
Decrease (90 %)
NA
31809045
DrugRepV_80385-{3-[2-carboxy-2-(3-{3-[2-({1-carboxy-2-[2-(3,5-dicarboxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)ethoxy]-2,2-bis({[2-({1-carboxy-2-[2-(3,5-dicarboxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)ethoxy]methyl})propoxy}propanamido)ethyl]-1H-indol-2-yl}benzene-1
NA
NA
Enterovirus
BrCr
Pathway
NA
Decrease (90 %)
NA
31809045
DrugRepV_8039MADAL-385
NA
NA
Enterovirus
11316
Pathway
NA
Decrease (50 %)
NA
31809045
DrugRepV_80405-(3-{2-carboxy-2-[6-({1-carboxy-2-[2-(3,5-dicarboxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)-4-[2-({1-carboxy-2-[2-(3,5-dicarboxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)ethyl]-4-nitrohexanamido]ethyl}-1H-indol-2-yl)benzene-1,3-dicarboxylic acid
NA
NA
Enterovirus
11316
Pathway
NA
Decrease (50 %)
NA
31809045
DrugRepV_80413-{3-[2-carboxy-2-(3-{3-[2-({1-carboxy-2-[2-(3-carboxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)ethoxy]-2,2-bis({[2-({1-carboxy-2-[2-(3-carboxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)ethoxy]methyl})propoxy}propanamido)ethyl]-1H-indol-2-yl}benzoic acid
NA
NA
Enterovirus
11316
Pathway
NA
Decrease (50 %)
NA
31809045
DrugRepV_80425-{3-[2-carboxy-2-(3-{3-[2-({1-carboxy-2-[2-(3,5-dicarboxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)ethoxy]-2,2-bis({[2-({1-carboxy-2-[2-(3,5-dicarboxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)ethoxy]methyl})propoxy}propanamido)ethyl]-1H-indol-2-yl}benzene-1
NA
NA
Enterovirus
11316
Pathway
NA
Decrease (50 %)
NA
31809045
DrugRepV_8043MADAL-385
NA
NA
Enterovirus
TW/70902/08
Pathway
NA
Decrease (50 %)
NA
31809045
DrugRepV_80445-(3-{2-carboxy-2-[6-({1-carboxy-2-[2-(3,5-dicarboxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)-4-[2-({1-carboxy-2-[2-(3,5-dicarboxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)ethyl]-4-nitrohexanamido]ethyl}-1H-indol-2-yl)benzene-1,3-dicarboxylic acid
NA
NA
Enterovirus
TW/70902/08
Pathway
NA
Decrease (50 %)
NA
31809045
DrugRepV_80453-{3-[2-carboxy-2-(3-{3-[2-({1-carboxy-2-[2-(3-carboxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)ethoxy]-2,2-bis({[2-({1-carboxy-2-[2-(3-carboxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)ethoxy]methyl})propoxy}propanamido)ethyl]-1H-indol-2-yl}benzoic acid
NA
NA
Enterovirus
TW/70902/08
Pathway
NA
Decrease (50 %)
NA
31809045
DrugRepV_80465-{3-[2-carboxy-2-(3-{3-[2-({1-carboxy-2-[2-(3,5-dicarboxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)ethoxy]-2,2-bis({[2-({1-carboxy-2-[2-(3,5-dicarboxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)ethoxy]methyl})propoxy}propanamido)ethyl]-1H-indol-2-yl}benzene-1
NA
NA
Enterovirus
TW/70902/08
Pathway
NA
Decrease (50 %)
NA
31809045
DrugRepV_8047MADAL-385
NA
NA
Enterovirus
H08300 461; 812
Pathway
NA
Decrease (50 %)
NA
31809045
DrugRepV_80485-(3-{2-carboxy-2-[6-({1-carboxy-2-[2-(3,5-dicarboxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)-4-[2-({1-carboxy-2-[2-(3,5-dicarboxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)ethyl]-4-nitrohexanamido]ethyl}-1H-indol-2-yl)benzene-1,3-dicarboxylic acid
NA
NA
Enterovirus
H08300 461; 812
Pathway
NA
Decrease (50 %)
NA
31809045
DrugRepV_80493-{3-[2-carboxy-2-(3-{3-[2-({1-carboxy-2-[2-(3-carboxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)ethoxy]-2,2-bis({[2-({1-carboxy-2-[2-(3-carboxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)ethoxy]methyl})propoxy}propanamido)ethyl]-1H-indol-2-yl}benzoic acid
NA
NA
Enterovirus
H08300 461; 812
Pathway
NA
Decrease (50 %)
NA
31809045
DrugRepV_80505-{3-[2-carboxy-2-(3-{3-[2-({1-carboxy-2-[2-(3,5-dicarboxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)ethoxy]-2,2-bis({[2-({1-carboxy-2-[2-(3,5-dicarboxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)ethoxy]methyl})propoxy}propanamido)ethyl]-1H-indol-2-yl}benzene-1
NA
NA
Enterovirus
H08300 461; 812
Pathway
NA
Decrease (50 %)
NA
31809045
DrugRepV_8051MADAL-385
NA
NA
Enterovirus
TW/1956/05
Pathway
NA
Decrease (50 %)
NA
31809045
DrugRepV_80525-(3-{2-carboxy-2-[6-({1-carboxy-2-[2-(3,5-dicarboxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)-4-[2-({1-carboxy-2-[2-(3,5-dicarboxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)ethyl]-4-nitrohexanamido]ethyl}-1H-indol-2-yl)benzene-1,3-dicarboxylic acid
NA
NA
Enterovirus
TW/1956/05
Pathway
NA
Decrease (50 %)
NA
31809045
DrugRepV_80533-{3-[2-carboxy-2-(3-{3-[2-({1-carboxy-2-[2-(3-carboxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)ethoxy]-2,2-bis({[2-({1-carboxy-2-[2-(3-carboxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)ethoxy]methyl})propoxy}propanamido)ethyl]-1H-indol-2-yl}benzoic acid
NA
NA
Enterovirus
TW/1956/05
Pathway
NA
Decrease (50 %)
NA
31809045
DrugRepV_80545-{3-[2-carboxy-2-(3-{3-[2-({1-carboxy-2-[2-(3,5-dicarboxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)ethoxy]-2,2-bis({[2-({1-carboxy-2-[2-(3,5-dicarboxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)ethoxy]methyl})propoxy}propanamido)ethyl]-1H-indol-2-yl}benzene-1
NA
NA
Enterovirus
TW/1956/05
Pathway
NA
Decrease (50 %)
NA
31809045
DrugRepV_8298Gemcitabine
Antineoplastic and Immunomodulating Agents
Ovarian cancer | Non-small cell lung cance | Adenocarcinoma of the pancreas
Enterovirus
NA
Pathway
NA
Decrease (50 %)
Approved
32424333
DrugRepV_8463Pirodavir
NA
Picronavirus infection
Enterovirus
H
NA
Cytopathic effect (CPE) assay
Decrease (50 %)
Experimental
28081706
DrugRepV_8464Pirodavir
NA
Picronavirus infection
Enterovirus
SHZH98
NA
Cytopathic effect (CPE) assay
Decrease (50 %)
Experimental
28081706
DrugRepV_8465Pirodavir
NA
Picronavirus infection
Enterovirus
JS-52
NA
Cytopathic effect (CPE) assay
Decrease (50 %)
Experimental
28081706
DrugRepV_8466Pirodavir
NA
Picronavirus infection
Enterovirus
BrCr
NA
Cytopathic effect (CPE) assay
Decrease (50 %)
Experimental
28081706